Array BioPharma achieves milestone for dosing MEK inhibitor
Saturday, April 14, 2007 14:00 IST
AstraZeneca PLC dosed its first cancer patient in a phase 1 clinical trial with our MEK inhibitor, ARRY-704 (AZD8330), triggering a $2 million milestone payment from AstraZeneca to Array BioPharma Inc. In December 2003, Array partnered the oncology portion of its MEK programme, including its lead compound, ARRY-886 (AZD6244), for co-development and commercialisation with AstraZeneca.
The collaboration included research and development of additional clinical candidates, which resulted in the selection of ARRY-704 in December 2005.
ARRY-704 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. ARRY-704 has shown tumour suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.
Monday, April 16, 2007
Array BioPharma achieves milestone
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment